On August 24, 2025, Serena Williams, the 43-year-old tennis legend, faced backlash after announcing her partnership with GLP-1 medicine company Ro on Instagram, revealing her use of a weekly weight-loss injection, as reported by People. The endorsement, linked to her post-pregnancy journey, has drawn criticism for promoting a “dangerous” narrative about body image.
In the Instagram post, Williams explained that the medication helped her body’s needs after having two children, Adira (2023) and Olympia (2017). Critics on social media, however, expressed disappointment, with one user stating, “It’s a shame you’re reiterating the narrative that medication is needed for beauty,” per People. Others called the message “wrong” and “disturbing,” arguing it undermines natural recovery and sets a poor example for young athletes.
The backlash, trending on social media reflects concerns about her influence, given her 23 Grand Slam titles and 14 million followers. A 2025 Pew Research survey shows 62% of Americans view celebrity health endorsements skeptically, fearing unrealistic standards. Supporters, however, defend Williams’ transparency, citing her openness about post-pregnancy challenges, per Vogue. Williams has not yet addressed the criticism.
Read: Serena Williams Reveals Weight-Loss Medication Use for Transformation
The controversy highlights tensions around celebrity endorsements in the $4.4 billion weight-loss drug market, per Bloomberg. Williams’ partnership with Ro, alongside her $55 million net worth, underscores her evolving role as a wellness influencer. Critics argue her stature amplifies the impact, potentially pressuring young women, while her team emphasises personal choice and health.
As Williams navigates the backlash, fans await her response, potentially via Instagram or her docuseries In the Arena. The debate could spark broader discussions on body positivity in sports, with updates expected as she continues her wellness journey and business ventures like Serena Ventures.
